• Consensus Rating: Buy
  • Consensus Price Target: $310.91
  • Forecasted Upside: 8.10%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$287.60
▼ -4.57 (-1.56%)

This chart shows the closing price for PODD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Insulet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

Analyst Price Target is $310.91
▲ +8.10% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $310.91, with a high forecast of $345.00 and a low forecast of $245.00. The average price target represents a 8.10% upside from the last price of $287.60.

This chart shows the closing price for PODD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Insulet. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2023Wolfe ResearchInitiated CoveragePeer PerformN/A
1/6/2023Morgan StanleyBoost TargetEqual Weight$300.00 ➝ $320.00Low
1/4/2023BarclaysBoost Target$238.00 ➝ $245.00Low
12/12/2022Robert W. BairdBoost Target$315.00 ➝ $340.00Low
12/12/2022CitigroupBoost Target$270.00 ➝ $330.00Low
11/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$290.00 ➝ $310.00Low
11/4/2022BTIG ResearchBoost Target$285.00 ➝ $320.00Low
11/4/2022CitigroupBoost Target$260.00 ➝ $270.00Low
11/4/2022Morgan StanleyBoost TargetEqual Weight$273.00 ➝ $300.00Low
11/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$235.00 ➝ $340.00Low
11/4/2022Robert W. BairdBoost TargetOutperform$300.00 ➝ $315.00Low
11/4/2022Raymond JamesBoost TargetOutperform$280.00 ➝ $320.00Low
10/17/2022BarclaysInitiated CoverageEqual Weight$238.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$260.00Low
8/9/2022CitigroupBoost Target$260.00N/A
8/9/2022BTIG ResearchBoost Target$285.00N/A
8/8/2022Morgan StanleyBoost TargetEqual Weight$244.00 ➝ $273.00Low
8/8/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$250.00 ➝ $290.00Low
8/5/2022Canaccord Genuity GroupBoost TargetBuy$250.00 ➝ $290.00Low
8/5/2022Robert W. BairdBoost TargetOutperform$245.00 ➝ $300.00Low
8/5/2022Raymond JamesBoost Target$262.00 ➝ $280.00Low
8/5/2022Piper SandlerBoost TargetNeutral$230.00 ➝ $235.00Low
7/11/2022CitigroupDowngradeBuy ➝ Neutral$310.00 ➝ $250.00N/A
6/24/2022BTIG ResearchLower TargetBuy$310.00 ➝ $250.00Low
6/7/2022Morgan StanleyLower TargetEqual Weight$268.00 ➝ $244.00Low
5/17/2022CitigroupLower TargetBuy$350.00 ➝ $310.00N/A
5/6/2022Wells Fargo & CompanyLower Target$357.00 ➝ $345.00High
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
2/25/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $268.00High
2/24/2022Raymond JamesLower TargetOutperform$329.00 ➝ $280.00High
2/24/2022Robert W. BairdLower Target$315.00 ➝ $275.00High
2/24/2022Piper SandlerLower TargetNeutral$295.00 ➝ $230.00High
2/3/2022BTIG ResearchUpgradeNeutral ➝ Buy$320.00Medium
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$325.00Low
1/31/2022OppenheimerUpgradeMarket Perform ➝ Outperform$300.00 ➝ $275.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$303.00 ➝ $300.00High
12/7/2021SVB LeerinkReiterated RatingBuyHigh
11/8/2021Raymond JamesBoost TargetOutperform$285.00 ➝ $329.00Medium
11/5/2021Morgan StanleyBoost TargetEqual Weight$276.00 ➝ $303.00High
11/5/2021SVB LeerinkBoost TargetOutperform$300.00 ➝ $350.00High
11/5/2021CitigroupBoost TargetBuy$325.00 ➝ $350.00High
11/5/2021Piper SandlerBoost TargetNeutral$262.00 ➝ $295.00High
8/6/2021SVB LeerinkLower TargetOutperform$325.00 ➝ $300.00High
8/6/2021CitigroupBoost TargetBuy$310.00 ➝ $325.00High
7/21/2021CowenBoost TargetOutperform$285.00 ➝ $310.00Low
7/20/2021SVB LeerinkBoost TargetOutperform$300.00 ➝ $325.00Low
5/24/2021BarclaysInitiated CoverageOverweight$300.00Low
5/7/2021Raymond JamesLower TargetOutperform$296.00 ➝ $285.00High
5/7/2021SVB LeerinkLower TargetOutperform$320.00 ➝ $300.00High
5/7/2021Piper SandlerLower TargetNeutral$260.00 ➝ $250.00High
5/7/2021BTIG ResearchReiterated RatingHoldHigh
4/1/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$275.00 ➝ $320.00Low
3/2/2021SVB LeerinkBoost TargetMarket Perform$255.00 ➝ $275.00Low
2/25/2021OppenheimerBoost TargetMarket Perform$235.00 ➝ $277.00High
2/24/2021SVB LeerinkReiterated RatingMarket Perform$255.00 ➝ $275.00High
2/24/2021Raymond JamesBoost TargetOutperform$282.00 ➝ $296.00Low
2/1/2021BTIG ResearchReiterated RatingHoldLow
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$260.00Medium
1/15/2021Wells Fargo & CompanyReiterated RatingBuyMedium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$255.00 ➝ $268.00Medium
12/15/2020Morgan StanleyBoost TargetEqual Weight$246.00 ➝ $276.00Low
11/5/2020UBS GroupBoost TargetNeutral$230.00 ➝ $245.00Medium
11/5/2020Wells Fargo & CompanyBoost TargetOverweight$250.00 ➝ $266.00High
11/5/2020Raymond JamesBoost TargetOutperform$249.00 ➝ $250.00High
11/5/2020Morgan StanleyBoost TargetEqual Weight$232.00 ➝ $246.00High
10/12/2020SVB LeerinkBoost TargetMarket Perform$240.00 ➝ $255.00Low
8/7/2020Morgan StanleyBoost TargetEqual Weight$222.00 ➝ $232.00High
8/7/2020OppenheimerReiterated RatingHold$235.00Medium
8/7/2020StephensBoost TargetPositive ➝ Equal Weight$165.00 ➝ $230.00Medium
8/7/2020SVB LeerinkBoost TargetMarket Perform$215.00 ➝ $240.00Medium
8/7/2020Raymond JamesBoost TargetOutperform$200.00 ➝ $249.00Medium
8/7/2020CitigroupBoost TargetBuy$200.00 ➝ $255.00Medium
8/6/2020Piper SandlerReiterated RatingOverweight$235.00 ➝ $260.00Medium
7/28/2020Wells Fargo & CompanyInitiated CoverageOverweight$231.00High
7/7/2020CowenBoost TargetPositive ➝ Outperform$220.00 ➝ $230.00Low
6/9/2020Raymond JamesLower TargetOutperform$220.00 ➝ $200.00Low
5/8/2020CfraBoost TargetSell$162.00 ➝ $179.00Low
5/8/2020UBS GroupBoost TargetNeutral$195.00 ➝ $213.00High
5/8/2020Stifel NicolausBoost TargetHold$161.00 ➝ $195.00High
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$200.00 ➝ $235.00High
5/8/2020Robert W. BairdBoost Target$189.00 ➝ $242.00High
5/8/2020Morgan StanleyBoost TargetEqual Weight$186.00 ➝ $222.00Medium
5/8/2020SVB LeerinkBoost TargetMarket Perform$200.00 ➝ $230.00High
5/8/2020CitigroupBoost TargetBuy$206.00 ➝ $250.00High
4/27/2020Raymond JamesBoost TargetOutperform$205.00 ➝ $220.00Medium
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/3/2020Bank of AmericaInitiated CoverageNeutral$200.00Medium
3/31/2020Berenberg BankDowngradeBuy ➝ HoldHigh
3/27/2020Morgan StanleyBoost TargetEqual Weight$181.00 ➝ $186.00Low
3/27/2020CitigroupLower TargetBuy$220.00 ➝ $206.00Medium
3/4/2020CitigroupInitiated CoverageBuy$220.00Low
2/26/2020Piper SandlerReiterated RatingBuy$200.00High
2/26/2020CowenReiterated RatingBuyHigh
2/26/2020CfraLower TargetSell$163.00 ➝ $162.00Low
2/26/2020Robert W. BairdLower TargetOutperform$225.00 ➝ $215.00High
2/26/2020BTIG ResearchReiterated RatingHoldHigh
2/26/2020Raymond JamesLower TargetOutperform$213.00 ➝ $205.00High
2/6/2020Raymond JamesBoost TargetOutperform$158.00 ➝ $213.00Medium
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$170.00 ➝ $200.00Medium
12/17/2019Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $181.00Low
12/10/2019CfraInitiated CoverageSell$163.00Medium
11/18/2019Piper Jaffray CompaniesBoost TargetOverweight$170.00 ➝ $200.00Low
11/6/2019Raymond JamesBoost TargetOutperform$135.00 ➝ $158.00High
11/6/2019Piper Jaffray CompaniesReiterated RatingOverweight$160.00 ➝ $170.00High
10/22/2019Stifel NicolausInitiated CoverageHold$163.00High
10/21/2019CowenSet TargetBuy$165.00Medium
10/14/2019BTIG ResearchDowngradeBuy ➝ NeutralMedium
10/4/2019UBS GroupDowngradeBuy ➝ Neutral$155.00 ➝ $160.00Low
10/3/2019GuggenheimDowngradeBuy ➝ NeutralMedium
9/24/2019SVB LeerinkBoost TargetOutperform$160.00 ➝ $185.00High
9/23/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/6/2019Morgan StanleyBoost TargetEqual Weight$127.00 ➝ $135.00High
8/6/2019BTIG ResearchBoost TargetBuy$140.00High
8/6/2019BMO Capital MarketsBoost TargetOutperform$130.00 ➝ $150.00High
8/6/2019Jefferies Financial GroupBoost TargetBuy$105.00 ➝ $140.00High
8/6/2019Raymond JamesBoost TargetOutperform$125.00 ➝ $135.00High
8/6/2019GuggenheimBoost TargetBuy ➝ Positive$100.00 ➝ $145.00High
8/6/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$120.00 ➝ $155.00High
8/6/2019Piper Jaffray CompaniesBoost TargetOverweight$130.00 ➝ $160.00High
7/16/2019Morgan StanleyBoost TargetEqual Weight$98.00 ➝ $127.00Low
7/10/2019SVB LeerinkReiterated RatingOutperformLow
6/28/2019Piper Jaffray CompaniesBoost TargetOverweight ➝ Positive$110.00 ➝ $130.00High
6/27/2019JPMorgan Chase & Co.Boost TargetNeutral$90.00 ➝ $120.00Low
6/13/2019UBS GroupBoost TargetBuy$110.00 ➝ $130.00Low
6/10/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$100.00Low
5/6/2019BTIG ResearchUpgradeNeutral ➝ Buy$115.00High
2/26/2019OppenheimerSet TargetHold$100.00Medium
2/26/2019Northland SecuritiesReiterated RatingBuy$100.00High
1/3/2019SVB LeerinkReiterated RatingOutperform$110.00 ➝ $100.00Medium
1/2/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$105.00 ➝ $90.00High
11/27/2018UBS GroupInitiated CoverageBuy$105.00Medium
11/2/2018OppenheimerSet TargetHold$100.00High
10/11/2018Morgan StanleyBoost TargetEqual Weight$96.00 ➝ $105.00Medium
9/11/2018SVB LeerinkReiterated RatingOutperform$130.00Medium
8/3/2018Jefferies Financial GroupReiterated RatingBuy$97.00Low
8/3/2018OppenheimerSet TargetHold$96.00High
7/10/2018BMO Capital MarketsBoost TargetTop Pick$115.00Medium
6/4/2018Piper Jaffray CompaniesBoost TargetOverweight$106.00Low
6/1/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$87.00 ➝ $96.00Low
5/4/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$90.00 ➝ $100.00High
5/4/2018Northland SecuritiesReiterated RatingBuy$100.00Low
5/4/2018OppenheimerSet TargetHold$90.00High
5/3/2018Piper Jaffray CompaniesBoost TargetOverweight$88.00 ➝ $90.00High
4/20/2018Berenberg BankInitiated CoverageBuy$100.00Medium
4/3/2018GuggenheimInitiated CoverageBuy$105.00Low
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$90.00High
2/23/2018Jefferies Financial GroupReiterated RatingBuy$90.00Low
2/22/2018CowenReiterated RatingOutperform ➝ Outperform$80.00 ➝ $90.00Medium
2/22/2018OppenheimerSet TargetHold$82.00High
2/22/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$76.00 ➝ $87.00High
2/22/2018StephensReiterated RatingEqual Weight ➝ Equal Weight$60.00 ➝ $81.00High
2/22/2018BarclaysReiterated RatingOverweight ➝ Overweight$85.00 ➝ $90.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 5 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
9/10/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/9/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 15 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 15 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Insulet logo
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Read More

Today's Range

Now: $287.60
Low: $283.01
High: $290.97

50 Day Range

MA: $296.24
Low: $279.72
High: $313.00

52 Week Range

Now: $287.60
Low: $181.00
High: $320.00

Volume

35,941 shs

Average Volume

365,530 shs

Market Capitalization

$19.97 billion

P/E Ratio

1,198.33

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Bank of America Co., Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

11 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $310.91, suggesting a possible upside of 6.4%. Wells Fargo & Company has the highest price target set, predicting PODD will reach $345.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $245.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PODD will outperform the market and that investors should add to their positions of Insulet.
View the latest ratings for PODD.

What other companies compete with Insulet?

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is (978) 600-7000 and its investor relations email address is [email protected] The official website for Insulet is www.insulet.com. Learn More about contacing Insulet investor relations.